Live Attenuated and Inactivated Influenza Vaccine Effectiveness. 2019

Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia; JChung@cdc.gov.

Researchers in observational studies of vaccine effectiveness (VE) in which they compared quadrivalent live attenuated vaccine (LAIV4) and inactivated influenza vaccine (IIV) among children and adolescents have shown inconsistent results, and the studies have been limited by small samples. We combined data from 5 US studies from 2013-2014 through 2015-2016 to compare the VE of LAIV4 and IIV against medically attended, laboratory-confirmed influenza among patients aged 2 to 17 years by influenza season, subtype, age group, and prior vaccination status. The VE of IIV or LAIV4 was calculated as 100% × (1 - odds ratio), comparing the odds of vaccination among patients who were influenza-positive to patients who were influenza-negative from adjusted logistic regression models. Relative effectiveness was defined as the odds of influenza comparingLAIV4 and IIV recipients. Of 17 173 patients aged 2 to 17 years, 4579 received IIV, 1979 received LAIV4, and 10 615 were unvaccinated. Against influenza A/H1N1pdm09, VE was 67% (95% confidence interval [CI]: 62% to 72%) for IIV and 20% (95% CI: -6% to 39%) for LAIV4. Results were similar when stratified by vaccination in the previous season. LAIV4 recipients had significantly higher odds of influenza A/H1N1pdm09 compared with IIV recipients (odds ratio 2.66; 95% CI: 2.06 to 3.44). LAIV4 and IIV had similar effectiveness against influenza A/H3N2 and B. Our overall findings were consistent when stratified by influenza season and age group. From this pooled individual patient-level data analysis, we found reduced effectiveness of LAIV4 against influenza A/H1N1pdm09 compared with IIV, which is consistent with published results from the individual studies included.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated

Related Publications

Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
September 2016, American journal of preventive medicine,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
May 2017, Vaccine,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
May 1990, American journal of diseases of children (1960),
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
February 2010, Experimental & molecular medicine,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
October 2018, JAMA network open,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
February 2007, The New England journal of medicine,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
November 2000, Nihon rinsho. Japanese journal of clinical medicine,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
January 2015, Current topics in microbiology and immunology,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
February 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Jessie R Chung, and Brendan Flannery, and Christopher S Ambrose, and Rodolfo E Bégué, and Herve Caspard, and Laurie DeMarcus, and Ashley L Fowlkes, and Geeta Kersellius, and Andrea Steffens, and Alicia M Fry, and , and , and
June 2008, Vaccine,
Copied contents to your clipboard!